{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,10]],"date-time":"2026-04-10T15:10:03Z","timestamp":1775833803124,"version":"3.50.1"},"reference-count":42,"publisher":"Wiley","issue":"1","license":[{"start":{"date-parts":[[2017,11,17]],"date-time":"2017-11-17T00:00:00Z","timestamp":1510876800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"funder":[{"DOI":"10.13039\/501100007155","name":"Medical Research Council Canada","doi-asserted-by":"publisher","award":["G:0900466"],"award-info":[{"award-number":["G:0900466"]}],"id":[{"id":"10.13039\/501100007155","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100011102","name":"Seventh Framework Programme","doi-asserted-by":"publisher","award":["316655"],"award-info":[{"award-number":["316655"]}],"id":[{"id":"10.13039\/100011102","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Reviews in Medical Virology"],"published-print":{"date-parts":[[2018,1]]},"abstract":"<jats:title>Summary<\/jats:title><jats:p>In this review article, we consider results suggesting that transmission of human cytomegalovirus (HCMV) from a donor of a solid organ to an immunologically naive individual can be reduced. Two randomized controlled trials have been conducted recently, one of active immunization of recipients pretransplant and another of passive immunization with monoclonal antibodies specific for HCMV given at the time of transplant. Although the available data are encouraging\u2014providing evidence of a reduction in the incidence of HCMV viraemia\u2014they fall short of what would be required to prove definitively that transmission has been completely prevented. Here, we reflect on these studies and propose a set of 5 criteria, which, if satisfied in the future, could be taken as proof that active and\/or passive immunization against HCMV effectively interrupts transmission of virus from the donor. We suggest that these criteria are considered when designing future randomized controlled trials.<\/jats:p>","DOI":"10.1002\/rmv.1958","type":"journal-article","created":{"date-parts":[[2017,11,17]],"date-time":"2017-11-17T10:43:00Z","timestamp":1510915380000},"source":"Crossref","is-referenced-by-count":13,"title":["Criteria to define interruption of transmission of human cytomegalovirus from organ donor to recipient"],"prefix":"10.1002","volume":"28","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-0224-8857","authenticated-orcid":false,"given":"Ilona Anna","family":"Baraniak","sequence":"first","affiliation":[{"name":"Centre for Virology UCL Medical School  London UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Matthew B.","family":"Reeves","sequence":"additional","affiliation":[{"name":"Centre for Virology UCL Medical School  London UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Paul D.","family":"Griffiths","sequence":"additional","affiliation":[{"name":"Centre for Virology UCL Medical School  London UK"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2017,11,17]]},"reference":[{"key":"e_1_2_9_2_1","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciw668"},{"key":"e_1_2_9_3_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1600-6143.2012.04087.x"},{"key":"e_1_2_9_4_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(00)02350-3"},{"key":"e_1_2_9_5_1","doi-asserted-by":"publisher","DOI":"10.1097\/TP.0b013e31829df29d"},{"key":"e_1_2_9_6_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1600-6143.2004.00382.x"},{"key":"e_1_2_9_7_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1600-6143.2010.03074.x"},{"key":"e_1_2_9_8_1","doi-asserted-by":"publisher","DOI":"10.1097\/TP.0000000000001338"},{"key":"e_1_2_9_9_1","doi-asserted-by":"publisher","DOI":"10.1002\/rmv.1873"},{"key":"e_1_2_9_10_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(00)02607-6"},{"key":"e_1_2_9_11_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jcv.2016.04.013"},{"key":"e_1_2_9_12_1","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD005133.pub3"},{"key":"e_1_2_9_13_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(84)90930-9"},{"key":"e_1_2_9_14_1","doi-asserted-by":"publisher","DOI":"10.1002\/(SICI)1096-9071(199706)52:2<200::AID-JMV14>3.0.CO;2-O"},{"key":"e_1_2_9_15_1","doi-asserted-by":"publisher","DOI":"10.1086\/514145"},{"key":"e_1_2_9_16_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(11)60136-0"},{"key":"e_1_2_9_17_1","doi-asserted-by":"publisher","DOI":"10.1002\/rmv.645"},{"issue":"2","key":"e_1_2_9_18_1","doi-asserted-by":"crossref","DOI":"10.1128\/AAC.01794-16","article-title":"Phase 2 randomized, double\u2010blind, placebo\u2010controlled trial of RG7667, a combination monoclonal antibody, for prevention of cytomegalovirus infection in high\u2010risk kidney transplant recipients","volume":"61","author":"Ishida JH","year":"2017","journal-title":"Antimicrob Agents Chemother"},{"key":"e_1_2_9_19_1","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00523-15"},{"key":"e_1_2_9_20_1","doi-asserted-by":"publisher","DOI":"10.1111\/tid.12205"},{"key":"e_1_2_9_21_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40265-016-0653-5"},{"issue":"1","key":"e_1_2_9_22_1","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1097\/00007890-199307000-00019","article-title":"The prognostic significance of positive CMV cultures during surveillance of renal transplant recipients","volume":"56","author":"Pillay D","year":"1993","journal-title":"Transplantation"},{"key":"e_1_2_9_23_1","doi-asserted-by":"publisher","DOI":"10.1097\/00007890-199310000-00018"},{"key":"e_1_2_9_24_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa0804749"},{"key":"e_1_2_9_25_1","doi-asserted-by":"publisher","DOI":"10.1084\/jem.20050882"},{"key":"e_1_2_9_26_1","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1007\/978-1-62703-788-4_6","article-title":"The use of primary human cells (fibroblasts, monocytes, and others) to assess human cytomegalovirus function","volume":"1119","author":"Poole E","year":"2014","journal-title":"Methods Mol Biol"},{"key":"e_1_2_9_27_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2007-01-070078"},{"key":"e_1_2_9_28_1","doi-asserted-by":"publisher","DOI":"10.1002\/rmv.1862"},{"key":"e_1_2_9_29_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00281-014-0447-3"},{"key":"e_1_2_9_30_1","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2013.00458"},{"key":"e_1_2_9_31_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2012-10-459545"},{"key":"e_1_2_9_32_1","first-page":"6","article-title":"Control of immune ligands by members of a cytomegalovirus gene expansion suppresses natural killer cell activation","volume":"10","author":"Fielding CA","year":"2017","journal-title":"Elife"},{"key":"e_1_2_9_33_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.immuni.2015.02.013"},{"key":"e_1_2_9_34_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.immuni.2015.02.008"},{"issue":"7","key":"e_1_2_9_35_1","doi-asserted-by":"crossref","DOI":"10.1097\/TXD.0000000000000605","article-title":"Human cytomegalovirus infection enhances NK cell activity in vitro","volume":"2","author":"Tschan\u2010Plessl A","year":"2016","journal-title":"Transplantation direct"},{"key":"e_1_2_9_36_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1473-3099(12)70197-4"},{"key":"e_1_2_9_37_1","doi-asserted-by":"publisher","DOI":"10.1002\/path.4437"},{"key":"e_1_2_9_38_1","doi-asserted-by":"publisher","DOI":"10.1084\/jem.190.2.177"},{"key":"e_1_2_9_39_1","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.140123497"},{"key":"e_1_2_9_40_1","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/cit048"},{"key":"e_1_2_9_41_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.cell.2014.04.028"},{"issue":"2","key":"e_1_2_9_42_1","article-title":"Seropositivity to cytomegalovirus, inflammation, all\u2010cause and cardiovascular disease\u2010related mortality in the United States","volume":"6","author":"Simanek AM","year":"2011","journal-title":"PLo SONE"},{"key":"e_1_2_9_43_1","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/cit083"}],"container-title":["Reviews in Medical Virology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Frmv.1958","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/rmv.1958","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,29]],"date-time":"2023-09-29T07:13:52Z","timestamp":1695971632000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1002\/rmv.1958"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,11,17]]},"references-count":42,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2018,1]]}},"alternative-id":["10.1002\/rmv.1958"],"URL":"https:\/\/doi.org\/10.1002\/rmv.1958","archive":["Portico"],"relation":{},"ISSN":["1052-9276","1099-1654"],"issn-type":[{"value":"1052-9276","type":"print"},{"value":"1099-1654","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,11,17]]},"article-number":"e1958"}}